Skip to main content
Medications for Motor Symptoms

Gocovri (extended-release amantadine)

About

Gocovri was approved in 2017 by the U.S. Food and Drug Administration (FDA) as the first drug specifically indicated for levodopa-induced dyskinesia (irregular, involuntary, uncontrolled movements). The Michael J. Fox Foundation helped moved this drug to market by supporting the creation and authentication of the Unified Dyskinesia Rating Scale, a tool that was used to measure Gocovri's impact in trials.

Gocovri works on the dopamine and glutamate brain chemical pathways. The medication is a long-acting formulation of amantadine, a drug that has been available for many years. Gocovri is a capsule that is intended to be taken once daily, at bedtime, so that drug levels are highest during the day, when dyskinesia typically is most bothersome.

Pros

In addition to easing dyskinesia, this drug also may decrease total daily "off" time (when symptoms are not well controlled because Parkinson's medications are not working optimally).

For many, the once-daily dosing may be advantageous, especially if they are on otherwise complex medication regimens.

Cons and Complications

Gocovri could cause hallucinations (seeing things that aren't there), dizziness, dry mouth, swelling of the legs and feet, constipation and falls. In people who have kidney problems, the dose may need to be decreased.


The medical information contained in this article is for general information purposes only. The Michael J. Fox Foundation for Parkinson's Research has a policy of refraining from advocating, endorsing or promoting any drug therapy, course of treatment, or specific company or institution. It is crucial that care and treatment decisions related to Parkinson's disease and any other medical condition be made in consultation with a physician or other qualified medical professional.

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.